Kolexia
De Guibert Sophie Hématologie
De Guibert Sophie
Hématologie
Hôpital Pontchaillou
Rennes, France
130 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Leucémie chronique lymphocytaire à cellules B Leucémies Leucémie lymphoïde Lymphomes Lymphome B Hémoglobinurie Hémoglobinurie paroxystique Maladie résiduelle Lymphome B diffus à grandes cellules

Collaborateurs

Voir plus
Ysebaert Loic
Ysebaert Loic
Oncopole Toulouse, Toulouse, France
Lepretre Stephane
Lepretre Stephane
Centre Henri-Becquerel, Rouen, France
Leblond Véronique
Leblond Véronique
Hôpital Pitie Salpetriere, Paris, France
Dilhuydy Marie-Sarah
Dilhuydy Marie-Sarah
Hôpital Haut-lévêque, Pessac, France

Industries

Voir plus
Janssen
30 collaboration(s)
Dernière en 2023
Abbvie
26 collaboration(s)
Dernière en 2023
AstraZeneca
20 collaboration(s)
Dernière en 2023
Novartis
8 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry
Essai Clinique (Alexion)   29 février 2024
BRUIN-CLL-314: A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-314)
Essai Clinique (Loxo Oncology, Inc.)   24 janvier 2024
BRUIN CLL-322: A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322)
Essai Clinique (Loxo Oncology, Inc.)   24 janvier 2024
Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroids.
Bone marrow transplantation   04 janvier 2024
Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia: Efficacy of First Line Dexamethasone, Rituximab and Cyclophosphamide (DRC) +/- Bortezomib for Patients With Waldenström's Macroglobulinemia
Essai Clinique (University of Ulm)   29 novembre 2023
Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Interim Results of MRD Kinetics in the Eradic Trial from the Filo Group
65th ASH Annual Meeting Abstracts   02 novembre 2023
Lenalidomide Consolidation Improves Measurable Residual Disease (MRD) Rates and Progression Free Survival in Patients with Chronic Lymphocytic Leukemia Following Initial FCR Chemotherapy - Final Analysis of CLL6 Residuum Study of the Australian Leukaemia and Lymphoma Group (ALLG) and the French Innovative Leukemia Organization (FILO)
65th ASH Annual Meeting Abstracts   02 novembre 2023
THEMIS: Targeted Therapies in Chronic Lymphocytic Leukemia and Medico-economic Evaluation of the Ambulatory Medical Assistance Nurse Program : a Prospective Multicenter Randomized Study
Essai Clinique (CHU Toulouse)   18 septembre 2023
A fixed-duration immunochemotherapy approach in CLL: 5.5-year results from the phase 2 ICLL-07 FILO trial.
Blood advances   28 juillet 2023
Les actualités incontournables dans la biologie
Edimark   01 juillet 2023